Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma has executed a definitive collaborative agreement with IDIS, for the supply and distribution within the EU of the company's investigational drug orBec for the treatment of gastrointestinal graft-versus-host disease via a named patient program.
Subscribe to our email newsletter
Under a named patient program (NPP), investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the European Medicines Evaluation Agency (EMEA) or a national health authority. The NPP will allow Dor to provide a treatment option to patients with gastrointestinal graft-versus-host disease, an unmet medical need.
John Lagus, vice president of business development at IDIS, said: “We are delighted to be working with Dor to provide patients with gastrointestinal graft-versus-host disease access to orBec, so they can benefit from Dor’s innovative therapy.
“IDIS will work in close partnership with Dor to manage named patient program requests in a way that is reliable and responsible while ensuring that all the regulatory obligations are met.”